secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0001193125-22-240127
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports 23% response rate in RAS/MAPK-altered non-CRC tumors; combo trial in H1 2023
--------------------------------------------------------------------------------

- 23% (6/26) of RAS/MAPK-altered non-CRC solid tumor patients responded to single-agent ERAS-007 or ERAS-601.
- 44% (4/9) of BRAF-driven non-CRC solid tumor patients responded (1 confirmed PR, 3 unconfirmed PRs).
- Favorable safety profiles with largely non-overlapping, manageable treatment-related adverse events.
- Company plans to initiate ERAS-007 + ERAS-601 (MAPKlamp) dose escalation trial in first half of 2023.
- Retrospective pooled analysis included HERKULES-1, FLAGSHP-1, and ASN007-101 trials with data cutoffs through July 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000119312522240127/0001193125-22-240127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000119312522240127/d399259d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-240127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer